Eluvia Demonstrated a
Statistically Significant TLR Reduction of Greater Than 70%
in diabetic patients, compared to Zilver PTX
Hear IMPERIAL Principal Investigator, William Gray, MD share his perspectives on what the data means for diabetic patients.
IMPERIAL Diabetic Subgroup Analysis
Objective
This subgroup analysis provides clinical data on the safety and effectiveness of the Boston Scientific Corporation ELUVIA™ Drug-Eluting Vascular Stent System for treating Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA) lesions in the Diabetic patient population.
Diabetic Subgroup Baseline Characteristics
12-Month Primary Patency Results1
Eluvia demonstrated 87.4% primary patency versus 80.2% for Zilver PTX in the IMPERIAL Diabetic Subgroup.
1. Kaplan Meier Estimate: Primary patency as determined by duplex ultrasound (DUS) Peak Systolic Velocity Ratio (PSVR) is ≤ 2.4 at the 12-month follow-up visit, in the absence of clinically-driven TLR or bypass of the target lesion.
12-Month TLR Rate
Eluvia demonstrated a statistically significant reduction in TLR of greater than 70% in diabetic patients.
Eluvia demonstrated a 9-fold, statistically significant lower stent thrombosis rate compared to Zilver PTX in diabetic patients.
Eluvia has demonstrated remarkable and consistent primary patency
Stay Up to Date
Receive emails about the latest drug-eluting technology news, innovations and events in your area.
Explore DE Resources
Get physician perspectives, clinical data sheets and other resources about drug-eluting innovations.